135 - Rubraca assay for ovarian cancer; tolvaptan in inherited kidney disorder; halting of trastuzumab biosimilar approval; FDA promotes artificial intelligence in health care
Archived series ("Inactive feed" status)
When? This feed was archived on October 07, 2018 00:40 (). Last successful fetch was on August 31, 2018 22:03 ()
Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.
What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 204291182 series 1587676
April 27, 2018
Please subscribe, rate and review if you like this podcast. Thank you! The podcast website is http://newfdaapprovals.com
1:11 FDA approves first assay to identify Rubraca benefit among women with ovarian cancer https://www.curetoday.com/articles/fda-approves-first-assay-to-identify-rubraca-benefit-among-women-with-ovarian-cancer
3:27 FDA OKs Otsuka's tolvaptan to slow kidney function decline in inherited kidney cyst disorder https://www.otsuka-us.com/discover/articles-1188
5:16 US FDA halts approval for Pfizer’s trastuzumab biosimilar https://www.biopharma-reporter.com/Article/2018/04/24/US-FDA-halts-approval-for-Pfizer-s-trastuzumab-biosimilar
6:59 FDA chief moves to promote artificial intelligence in health care http://thehill.com/policy/healthcare/385020-fda-chief-moves-to-promote-artificial-intelligence-in-health-care
Brought to you by Nascent Medical. For assistance with medical writing, please email info@nascentmc.com.
Music credit: freemusicarchive.org/music/MindsEye/Yellow_Taxi/
100 episodes